That was part of my confusion also. I don't have the patience or ability to analyze the article in depth, but they keep switching between hypothalamus effects, CCL5, CCR5,and insulin sensitivity. That's why I went to the conclusion. I didn't really look at the methodology, but I wonder which CCR5 antagonist they could have used. Hopefully, just as an after thought, they didn't borrow some leronlimab.